ArticleBlood2025
Dissection of single-cell landscapes for the development of chimeric antigen receptor T cells in Hodgkin lymphoma.
Abstract read
In one paragraph
Article in Blood, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Impact of beta blockers on cancer neuroimmunology: a systematic review and meta-analysis of survival outcomes and immune modulation.Frontiers in immunology · 2025Pooled it
- Overcoming fratricide of CD86 targeting CAR-T cells by defined logic-gate CAR strategy.Experimental hematology & oncology · 2026Article
- The Hodgkin Lymphoma Microenvironment: Insights from Spatial Transcriptomics.International journal of molecular sciences · 2026Review
- Multi-omics analysis reveals that CAPG positive macrophages are key immunosuppressive drivers and prognostic determinants in the ferroptosis landscape of hepatocellular carcinoma.Discover oncology · 2026Article
- Ipilimumab with and without nivolumab in patients with classic Hodgkin lymphoma with progression after PD-1 blockade.Blood neoplasia · 2026Article
- Evolution of therapeutic paradigms in Hodgkin lymphoma: from "cure-oriented" to "functional cure".Frontiers in oncology · 2026Review
- Metabolic Interactions in the Tumor Microenvironment of Classical Hodgkin Lymphoma: Implications for Targeted Therapy.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
47 authors.
Adrian GottschlichDepartment of Medicine III, Ludwig Maximilian University Hospital, Ludwig Maximilian University Munich, Munich, Germany.ORCID 0000-0002-2898-4182
Ruth GrünmeierDivision of Clinical Pharmacology, Ludwig Maximilian University Hospital, Ludwig Maximilian University Munich, Member of the German Center for Lung Research, Munich, Germany.ORCID 0000-0002-9044-3600
Gordon Victor HoffmannDivision of Clinical Pharmacology, Ludwig Maximilian University Hospital, Ludwig Maximilian University Munich, Member of the German Center for Lung Research, Munich, Germany.ORCID 0009-0007-3167-2124
Sayantan NandiDivision of Clinical Pharmacology, Ludwig Maximilian University Hospital, Ludwig Maximilian University Munich, Member of the German Center for Lung Research, Munich, Germany.
Vladyslav KavakaDepartment of Hand, Plastic, Reconstructive and Burn Surgery, BG Unfallklinik Tuebingen, Eberhard Karls University Tuebingen, Tuebingen, Germany.
Philipp Jie MüllerDivision of Clinical Pharmacology, Ludwig Maximilian University Hospital, Ludwig Maximilian University Munich, Member of the German Center for Lung Research, Munich, Germany.
Jakob JobstDivision of Clinical Pharmacology, Ludwig Maximilian University Hospital, Ludwig Maximilian University Munich, Member of the German Center for Lung Research, Munich, Germany.
Arman OnerDivision of Clinical Pharmacology, Ludwig Maximilian University Hospital, Ludwig Maximilian University Munich, Member of the German Center for Lung Research, Munich, Germany.ORCID 0000-0003-2754-5417
Rainer KaiserDepartment of Medicine I, LMU University Hospital, LMU Munich, Munich, Germany.ORCID 0000-0003-1750-3395
Jan GärtigDivision of Clinical Pharmacology, Ludwig Maximilian University Hospital, Ludwig Maximilian University Munich, Member of the German Center for Lung Research, Munich, Germany.
Ignazio PisedduDivision of Clinical Pharmacology, Ludwig Maximilian University Hospital, Ludwig Maximilian University Munich, Member of the German Center for Lung Research, Munich, Germany.
Stephanie Frenz-WiessnerDepartment of Pediatrics, Dr. von Hauner Children's Hospital, Ludwig Maximilian University Hospital, Ludwig Maximilian University Munich, Munich, Germany.ORCID 0000-0001-8862-3752
Savannah D FairleyDepartment of Pediatrics, Dr. von Hauner Children's Hospital, Ludwig Maximilian University Hospital, Ludwig Maximilian University Munich, Munich, Germany.ORCID 0009-0001-8310-2074
Heiko SchulzInstitute of Pathology, Faculty of Medicine, Ludwig Maximilian University Munich, Munich, Germany.
Veronika IglDivision of Clinical Pharmacology, Ludwig Maximilian University Hospital, Ludwig Maximilian University Munich, Member of the German Center for Lung Research, Munich, Germany.ORCID 0000-0003-4618-2383
Thomas Alexander JanertDivision of Clinical Pharmacology, Ludwig Maximilian University Hospital, Ludwig Maximilian University Munich, Member of the German Center for Lung Research, Munich, Germany.ORCID 0009-0007-2466-7650
Lea Di FinaDepartment of Medicine I, LMU University Hospital, LMU Munich, Munich, Germany.
Maité MulkersDepartment of Medicine I, LMU University Hospital, LMU Munich, Munich, Germany.ORCID 0009-0003-4402-2682
Moritz ThomasInstitute of AI for Health, Helmholtz Zentrum München-German Research Center for Environmental Health Neuherberg, Neuherberg, Germany.ORCID 0000-0002-8422-2414
Daria BriukhovetskaDivision of Clinical Pharmacology, Ludwig Maximilian University Hospital, Ludwig Maximilian University Munich, Member of the German Center for Lung Research, Munich, Germany.ORCID 0000-0002-2073-2335
Donjetë SimnicaDivision of Clinical Pharmacology, Ludwig Maximilian University Hospital, Ludwig Maximilian University Munich, Member of the German Center for Lung Research, Munich, Germany.ORCID 0000-0003-2286-1381
Emanuele CarliniDivision of Clinical Pharmacology, Ludwig Maximilian University Hospital, Ludwig Maximilian University Munich, Member of the German Center for Lung Research, Munich, Germany.
Christina Angeliki TsiveriotiDivision of Clinical Pharmacology, Ludwig Maximilian University Hospital, Ludwig Maximilian University Munich, Member of the German Center for Lung Research, Munich, Germany.ORCID 0009-0008-4055-1196
Marcel P TrefnyDivision of Clinical Pharmacology, Ludwig Maximilian University Hospital, Ludwig Maximilian University Munich, Member of the German Center for Lung Research, Munich, Germany.ORCID 0000-0001-6755-7899
Theo LorenziniDivision of Clinical Pharmacology, Ludwig Maximilian University Hospital, Ludwig Maximilian University Munich, Member of the German Center for Lung Research, Munich, Germany.ORCID 0000-0003-3377-032X
Florian MärklDivision of Clinical Pharmacology, Ludwig Maximilian University Hospital, Ludwig Maximilian University Munich, Member of the German Center for Lung Research, Munich, Germany.ORCID 0000-0003-4285-0380
Pedro MesquitaDivision of Clinical Pharmacology, Ludwig Maximilian University Hospital, Ludwig Maximilian University Munich, Member of the German Center for Lung Research, Munich, Germany.ORCID 0009-0007-4285-9269
Ruben BrabenecDivision of Clinical Pharmacology, Ludwig Maximilian University Hospital, Ludwig Maximilian University Munich, Member of the German Center for Lung Research, Munich, Germany.ORCID 0000-0002-8820-220X
Thaddäus StrzalkowskiDivision of Clinical Pharmacology, Ludwig Maximilian University Hospital, Ludwig Maximilian University Munich, Member of the German Center for Lung Research, Munich, Germany.ORCID 0000-0002-7191-0410
Sophia StockDepartment of Medicine III, Ludwig Maximilian University Hospital, Ludwig Maximilian University Munich, Munich, Germany.ORCID 0000-0002-5072-5013
Stefanos MichaelidesDivision of Clinical Pharmacology, Ludwig Maximilian University Hospital, Ludwig Maximilian University Munich, Member of the German Center for Lung Research, Munich, Germany.ORCID 0000-0002-9001-0207
Johannes HellmuthDepartment of Medicine III, Ludwig Maximilian University Hospital, Ludwig Maximilian University Munich, Munich, Germany.ORCID 0000-0001-8409-3037
Martin ThelenDepartment of General, Visceral, Thoracic, and Transplantation Surgery.ORCID 0000-0002-2785-9726
Sarah ReinkeHematopathology Section, Department of Pathology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.ORCID 0000-0001-9729-4030
Wolfram KlapperHematopathology Section, Department of Pathology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.
Pascal Francois GelebartDepartment of Clinical Science, University of Bergen, Bergen, Norway.ORCID 0000-0003-2434-8987
Leo NicolaiDepartment of Medicine I, LMU University Hospital, LMU Munich, Munich, Germany.ORCID 0000-0003-0776-5885
Carsten MarrInstitute of AI for Health, Helmholtz Zentrum München-German Research Center for Environmental Health Neuherberg, Neuherberg, Germany.
Eduardo BeltránInstitute of Clinical Neuroimmunology, Ludwig Maximilian University Hospital, Ludwig Maximilian University Munich, Munich, Germany.ORCID 0000-0002-7266-4098
Remco T A MegensInstitute of Cardiovascular Prevention, LMU Munich, Munich, Germany.ORCID 0000-0001-9871-6696
Christoph KleinDepartment of Pediatrics, Dr. von Hauner Children's Hospital, Ludwig Maximilian University Hospital, Ludwig Maximilian University Munich, Munich, Germany.
Fanny Baran-MarszakINSERM U978, University of Paris 13, Bobigny, France.
Andreas RosenwaldComprehensive Cancer Center Mainfranken, University Hospital Würzburg, Würzburg, Germany.
Michael von Bergwelt-BaildonDepartment of Medicine III, Ludwig Maximilian University Hospital, Ludwig Maximilian University Munich, Munich, Germany.
Paul J BröckelmannDepartment I of Internal Medicine, Faculty of Medicine and University Hospital of Cologne, University of Cologne, Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf and German Hodgkin Study Group, Cologne, Germany.ORCID 0000-0001-9662-9900
Stefan EndresDivision of Clinical Pharmacology, Ludwig Maximilian University Hospital, Ludwig Maximilian University Munich, Member of the German Center for Lung Research, Munich, Germany.ORCID 0000-0002-4703-537X
Sebastian KoboldDivision of Clinical Pharmacology, Ludwig Maximilian University Hospital, Ludwig Maximilian University Munich, Member of the German Center for Lung Research, Munich, Germany.ORCID 0000-0002-5612-4673
Funding
No grant is acknowledged in the PubMed record.
Abstract
abstractThe success of targeted therapies for hematological malignancies has heralded their potential as both salvage treatment and early treatment lines, reducing the need for high-dose, intensive, and often toxic chemotherapeutic regimens. For young patients with classic Hodgkin lymphoma (cHL), immunotherapies provide the possibility to lessen long-term, treatment-related toxicities. However, suitable therapeutic targets are lacking. By integrating single-cell dissection of the tumor landscape and an in-depth, single-cell-based off-tumor antigen prediction, we identify CD86 as a promising therapeutic target in cHL. CD86 is highly expressed on Hodgkin and Reed-Sternberg cancer cells and cHL-specific tumor-associated macrophages. We reveal CD86-CTLA-4 as a key suppressive pathway in cHL, driving T-cell exhaustion. Cellular therapies targeting CD86 had extraordinary efficacy in vitro and in vivo and were safe in immunocompetent mouse models without compromising bacterial host defense in sepsis models. Our results prove the potential value of anti-CD86 immunotherapies for treating cHL.
Indexed as
Hodgkin DiseaseImmunotherapy, AdoptiveReceptors, Chimeric AntigenT-LymphocytesAnimalsB7-2 AntigenCell Line, TumorFemaleHumansMiceSingle-Cell AnalysisB7-2 AntigenReceptors, Chimeric Antigen
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.